Kezar Life Sciences Inc
NASDAQ:KZR
NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

  • LAST PRICE
    0.7723
  • TODAY'S CHANGE (%)
    -0.0172 (-2.1786%)
  • Bid / Lots
    0.7705/ 1
  • Ask / Lots
    0.8138/ 8
  • Open / Previous Close
    0.7980 / 0.7895
  • Day Range
    0.7713
    0.7980
  • 52 Week Range
    0.6746
    3.1300
  • Volume
    425,070

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • May 10, 2024

  • May 9, 2024

      Show headlines and story abstract

    • 4:01PM ET on Thursday May 09, 2024 by Business Wire
      Companies Mentioned: KZR

      Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today reported financial results for the first quarter ended March 31, 2024 and provided a business update.

    • 4:01PM ET on Thursday May 09, 2024 by Dow Jones
      Companies Mentioned: KZR
      ---------------- --------------------- (unaudited) Cash, cash equivalents and marketable securities $ 179,798 $ 201,372 Total assets 199,130 221,235 Total current liabilities 16,161 17,744 Total noncurrent liabilities 13,848 15,921 Total stockholders' equity 169,121 187,570 Summary of Operations Data (In thousands except share and per share data) Three Months Ended March 31 ---------------------------- 2024 2023 ------------ -------------- (unaudited) Operating expenses: Research and development $ 17,172 $ 18,318 General and administrative 6,539 6,206 ---------- ---------- Total operating expenses 23,711 24,524 ---------- ---------- Loss from operations (23,711) (24,524) Interest income 2,453 2,695 Interest expense (400) (370) ---------- ---------- Net loss $ (21,658) $ (22,199) ========== ========== Net loss per common share, basic and diluted $ (0.30) $ (0.31) ========== ========== Weighted-average shares used to compute net loss per common share, basic and diluted 72,799,910 72,328,231 ========== ==========

    • 4:01PM ET on Thursday May 09, 2024 by Dow Jones
      Companies Mentioned: KZR
      Selected Balance Sheets Data (In thousands) March 31, 2024 December 31, 2023 ---------------- --------------------- (unaudited) Cash, cash equivalents and marketable securities $ 179,798 $ 201,372 Total assets 199,130 221,235 Total current liabilities 16,161 17,744 Total noncurrent liabilities 13,848 15,921 Total stockholders' equity 169,121 187,570 Summary of Operations Data (In thousands except share and per share data) Three Months Ended March 31 ---------------------------- 2024 2023 ------------ -------------- (unaudited) Operating expenses: Research and development $ 17,172 $ 18,318 General and administrative 6,539 6,206 ---------- ---------- Total operating expenses 23,711 24,524 ---------- ---------- Loss from operations (23,711) (24,524) Interest income 2,453 2,695 Interest expense (400) (370) ---------- ---------- Net loss $ (21,658) $ (22,199) ========== ========== Net loss per common share, basic and diluted $ (0.30) $ (0.31) ========== ========== Weighted-average shares used to compute net loss per common share, basic and diluted 72,799,910 72,328,231 ========== ==========

  • May 6, 2024

      Show headlines and story abstract

    • 4:05PM ET on Monday May 06, 2024 by Business Wire
      Companies Mentioned: KZR

      Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that the Compensation Committee of the company's Board of Directors granted two employees nonqualified stock options to purchase 164,000 shares of its common stock with an exercise price of $0.84 per share, which is equal to the closing price of Kezar's common stock on May 1, 2024, the grant date of the awards. The stock options were granted as an inducement award material to the individuals entering into employment with Kezar, in accordance with Nasdaq Listing Rule 5635(c)(4).

Peers Headlines